Candriam Luxembourg S.C.A. Raises Position in Baxter International Inc (NYSE:BAX)

Candriam Luxembourg S.C.A. boosted its stake in shares of Baxter International Inc (NYSE:BAX) by 30.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,913 shares of the medical instruments supplier’s stock after purchasing an additional 11,507 shares during the quarter. Candriam Luxembourg S.C.A.’s holdings in Baxter International were worth $3,219,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. LSV Asset Management acquired a new stake in shares of Baxter International during the 3rd quarter valued at approximately $1,623,000. Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Baxter International by 147.0% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 3,544 shares of the medical instruments supplier’s stock valued at $273,000 after acquiring an additional 2,109 shares during the period. Martingale Asset Management L P lifted its position in shares of Baxter International by 1.6% during the 3rd quarter. Martingale Asset Management L P now owns 722,269 shares of the medical instruments supplier’s stock valued at $55,681,000 after acquiring an additional 11,546 shares during the period. American International Group Inc. lifted its position in shares of Baxter International by 5.8% during the 3rd quarter. American International Group Inc. now owns 223,402 shares of the medical instruments supplier’s stock valued at $17,222,000 after acquiring an additional 12,169 shares during the period. Finally, CIBC World Markets Inc. lifted its position in shares of Baxter International by 170.3% during the 3rd quarter. CIBC World Markets Inc. now owns 152,117 shares of the medical instruments supplier’s stock valued at $11,727,000 after acquiring an additional 95,847 shares during the period. 86.41% of the stock is owned by hedge funds and other institutional investors.

BAX has been the subject of several research reports. Morgan Stanley lifted their price objective on Baxter International from $80.00 to $83.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 5th. Zacks Investment Research cut shares of Baxter International from a “buy” rating to a “hold” rating in a research note on Thursday, January 3rd. Credit Suisse Group started coverage on shares of Baxter International in a research note on Monday, December 17th. They set an “outperform” rating and a $77.00 price objective for the company. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $80.00 price target on shares of Baxter International in a research report on Friday, February 1st. Finally, Barclays upped their price target on shares of Baxter International from $72.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Monday. Four equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $78.31.

In other news, Director Thomas T. Stallkamp sold 1,638 shares of the company’s stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $73.75, for a total value of $120,802.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Thomas T. Stallkamp sold 3,187 shares of the stock in a transaction dated Friday, January 18th. The stock was sold at an average price of $70.00, for a total transaction of $223,090.00. Following the sale, the director now owns 9,418 shares in the company, valued at approximately $659,260. The disclosure for this sale can be found here. In the last 90 days, insiders sold 98,286 shares of company stock worth $7,399,039. Company insiders own 0.70% of the company’s stock.

BAX stock traded up $0.29 during trading on Monday, reaching $79.61. The stock had a trading volume of 1,572,155 shares, compared to its average volume of 3,061,437. The firm has a market capitalization of $40.84 billion, a P/E ratio of 26.10, a P/E/G ratio of 1.94 and a beta of 1.02. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.09 and a quick ratio of 1.50. Baxter International Inc has a 1-year low of $61.05 and a 1-year high of $82.25.

Baxter International (NYSE:BAX) last issued its earnings results on Thursday, January 31st. The medical instruments supplier reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The business had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.80 billion. Baxter International had a net margin of 14.60% and a return on equity of 19.10%. On average, sell-side analysts anticipate that Baxter International Inc will post 3.27 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Monday, April 1st. Stockholders of record on Friday, March 1st were paid a $0.19 dividend. The ex-dividend date of this dividend was Thursday, February 28th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.95%. Baxter International’s dividend payout ratio (DPR) is presently 24.92%.

ILLEGAL ACTIVITY NOTICE: This report was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/04/15/baxter-international-inc-bax-stake-boosted-by-candriam-luxembourg-s-c-a.html.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Recommended Story: Do investors pay a separate front-end load every time they buy additional shares?

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.